We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.64 | 18.23% | 4.15 | 3.50 | 4.80 | - | 423,867 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/3/2024 10:36 | the leaker! | elpirata | |
11/3/2024 22:40 | Imagine how Stephen Diggle must feel | canaletto | |
10/3/2024 22:38 | ....or two. vbrs, P. Snodgrass | jeffian | |
10/3/2024 20:35 | Well I wish you a further generation ..... | dominiccummings | |
10/3/2024 16:52 | As I am now 89 I suspect I am only good for another 5 years, at best. But I do remember discussing, in the 1980s, with a friend/cousin of the same age, whether or not we would make the millennium, and concluding the probability was around 50%. Which we both have. So who knows? | goatherd | |
09/3/2024 18:47 | You got me! But, actually, I really do not think that PRM is inevitably a hopeless cause. I suppose I accept it may be. But hope dawns eternally in the human heart - - - but then, if I am not human - - - | goatherd | |
09/3/2024 17:49 | Yes. You are clearly an alien, here to promote hopeless causes. | dominiccummings | |
09/3/2024 17:41 | Not really what I meant - and I don't see your logic (have you any, actually?). | goatherd | |
09/3/2024 17:32 | You mean it is MORE often? | dominiccummings | |
09/3/2024 16:38 | Have you enough data to back that "every 25 years". I think not. :-) | goatherd | |
09/3/2024 13:37 | Goatherd is like Dr Who. He regenerates himself every 25 years into a new Goatherd, then continues to cheer all PRM holders. | dominiccummings | |
09/3/2024 10:18 | February 2024 Abstract and Figures Single-cell proteomics is a powerful approach to precisely profile protein landscapes within individual cells toward a comprehensive understanding of proteomic functions and tissue and cellular states. The inherent challenges associated with limited starting material in single-cell analyses demands heightened analytical sensitivity. Just as advances in sample preparation maximize the amount of material that makes it from the cell to the mass spectrometer, we strive to maximize the number of ions that make it from ion source to the detector. In isobaric tagging experiments, limited reporter ion generation limits quantitative accuracy and precision. The combination of infrared photoactivation and ion parking circumvents the m/z dependence inherent in HCD, maximizing reporter generation and avoiding unintended degradation of TMT reporter molecules in a method we term activated ion-tandem mass tags (AI-TMT). The method was applied to single-cell human proteomes using 18-plex TMTpro, resulting in a 4-5-fold increase in reporter ion signal on average compared to conventional SPS-MS ³ approaches. AI-TMT enables faster duty cycles, higher throughput, and increased peptide identification and quantification. Comparative experiments showcase 4-5-fold lower injection times for AI-TMT, providing superior sensitivity without compromising accuracy. In all, AI-TMT enhances the sensitivity and dynamic range of proteomic experiments and is compatible with other techniques, including gas-phase fractionation and real-time searching, promising increased gains in the study of cellular heterogeneity and disease mechanisms. | pools2 | |
09/3/2024 08:46 | A heart attack if I remember correctly! | dominiccummings | |
09/3/2024 07:45 | We need a crazy Tony around again,proper pump merchant,wonder what his reward was for all that guff. | peverill | |
08/3/2024 21:59 | It's wonderful how with some of these dud shares one generation hands over to another, almost without mention with the new ethusiasts indistinguishable from the old. When is the centenary? | dominiccummings | |
08/3/2024 19:52 | Ah yes, TDM. MNT There was also MDX where the Bell lost heavily, I recall Anyone know what's happened to Mike Walters? Seems his site has been discontinued | sandcrab2 | |
08/3/2024 19:33 | Where fgnoms, lamby, Saul and the rest of the old gang these days? | sandcrab2 | |
08/3/2024 13:05 | If someone wants to take us over they have to get the agreement of CJP and the Diggles first. I rather doubt they will. | goatherd | |
08/3/2024 12:26 | We may have to go lower before going higher. We're in right location so it's a matter of time but tgat time might be 2 - 3 years, too long for some as there are other opportunities, each to their own but this will get taken over at some stage as its really too small to exist on its own 11 million market cap is probably away to high at this stage unfortunately | goggin | |
07/3/2024 18:40 | The current CEO of PRM is proving herself to be uninspiring imo. I’m still hopeful we may see 6p+ on the share price this year but without any update from PRM on the forward looking revenue outlook for 2024 it’s difficult to say. We’ll get the FY results over next couple of months. The forward guidance will be critical for share price progress. W41 | wrighty41 | |
05/3/2024 12:31 | I would expect that long term ownership of this stock would confirm everything one needs to know regarding an avatars neurological health. | monte1 | |
05/3/2024 12:04 | MAPPING THE MIND: NEUROLOGICAL BIOMARKERS Published 20/09/2023 The Randox Health Signature programme incorporates testing of six key neurological biomarkers to provide an analysis of your neurological health. GFAP D-Dimer GSTP1 IL-6 NDKA PARK 7 All of above biomarkers are also in Randox Stroke Array licenced from Proteome Sciences | colinhy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions